Exscientia (NASDAQ:EXAI – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Volatility and Risk
Exscientia has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Profitability
This table compares Exscientia and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exscientia | -882.09% | -49.10% | -33.13% |
| Immatics | -47.94% | -15.90% | -9.38% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exscientia | 0 | 4 | 0 | 0 | 2.00 |
| Immatics | 0 | 0 | 4 | 0 | 3.00 |
Exscientia currently has a consensus price target of $7.00, indicating a potential upside of 44.63%. Immatics has a consensus price target of $16.67, indicating a potential upside of 110.70%. Given Immatics’ stronger consensus rating and higher probable upside, analysts clearly believe Immatics is more favorable than Exscientia.
Insider and Institutional Ownership
41.6% of Exscientia shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.4% of Exscientia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Exscientia and Immatics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exscientia | $25.60 million | 24.72 | -$181.56 million | ($1.51) | -3.21 |
| Immatics | $58.44 million | 16.16 | -$104.98 million | ($0.66) | -11.98 |
Immatics has higher revenue and earnings than Exscientia. Immatics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
Summary
Immatics beats Exscientia on 10 of the 14 factors compared between the two stocks.
About Exscientia
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.
